Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025World Journal of Clinical Oncology

Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHongchao JiaoYXYan XuJLJunxin Li

Discussion

Loading...

Member takes

Overview

Observational analysis reveals lower TACE resistance rates and improved survival in advanced HCC, suggesting benefits of combination therapy.

Key Points

  • The combination therapy significantly reduced TACE resistance rates to 9.7% compared to 38.8% in the TACE-only group, indicating better treatment effectiveness.
  • Combined therapy improved progression-free survival from 9.1 months with TACE alone to 17.5 months, suggesting enhanced patient outcomes.
  • Analysis included 721 patients where 144 were matched; results were statistically significant, highlighting the study's robustness.
  • Adding PD-(L)1 inhibitors and targeted therapies to TACE may establish a new treatment standard for advanced liver cancer.],
  • simple_explanation
  • Combining specific cancer treatments can help patients with advanced liver cancer. This approach uses transarterial chemoembolization (TACE) along with PD-(L)1 inhibitors and targeted therapies. It shows that this combination reduces treatment resistance and leads to longer survival times. That means patients might live longer and have better chances against their cancer. 🩺} } } } } } ) } } } } ) } } } } } } ) ) } } ) } } } } ) ) ) } ) } } } ) } ) } } } ) } ) } ) } ) } ) } ) } ) } ) } ) ) } ) ) } ) ) } } } } } ) } ) } ) ) } ) } ) ) ) ) } ) ) ) } ) ) } ) } ) ) ) ) ) ) } ) } ) ) ) ) ) } ) ) ) ) ) ) ) } } } } ) } } } } ) } ) ) } ) ) } ) } ) } ) ) ) ) ) } ) } ) ) ) ) ) } } } } } } } } ) } } ) } ) ) } ) } ) ) ) ) ) } } } } } } } } ) } ) } } } ) ) ) ) } ) ) } ) ) } } } ) } ) ) ) ) ) ) ) } } } ) } ) ) ) ) ) } } } } } ) } ) } ) } ) ) } } } } } ) ) ) } } } ) } } } } } ) ) ) } ) ) } ) } ) ) } } )
  • ​
  • ​
  • ​
  • ​” ,
  • ​
  • ​” ,
  • ​
  • ​
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​
  • ​
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​” ,
  • ​ ​
  • ​” ,
  • ​
  • ​
  • ​” ,
  • ​
  • ​” ,

Cite This Study

Jiao et al. (2025) studied this question.

synapsesocial.com/papers/68af409acf1dd9ea359ec73ehttps://doi.org/10.5306/wjco.v16.i8.109419
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TACE Combined with PD-L1 Inhibitors Effectively Mitigates TACE Resistance in Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Study2025
  2. 2Efficacy and Safety of PD-1 Inhibitors Combined with Transarterial Chemoembolization (TACE) and targeted Therapy in Advanced Primary Hepatocellular Carcinoma2025
  3. 3Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series2025 · 3 citations
  4. 4Immune checkpoint blockade and transarterial chemoembolization in liver-limited hepatocellular carcinoma: new questions at the dawn of a new era2025
  5. 5Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis2025 · 7 citations